Back to Search
Start Over
A robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations.
- Source :
-
Bioanalysis [Bioanalysis] 2021 Apr; Vol. 13 (7), pp. 565-574. Date of Electronic Publication: 2021 Mar 26. - Publication Year :
- 2021
-
Abstract
- Aim: Ramucirumab, an anti-VEGFR2 monoclonal antibody, has been approved for the treatment of metastatic gastric and colorectal cancer. An assay measuring ramucirumab serum concentrations was needed to investigate its pharmacokinetics and concentration-response relationship. Results: An ELISA was developed and validated according to the international guidelines for ligand-binding assays. Ramucirumab calibration standards ranged from 0.125 to 40 mg/l. Low, middle and high quality controls were spiked at 0.2, 4 and 8 mg/l, respectively. The limits of quantification were established to be 0.125 and 10 mg/l for LLOQ and ULOQ, respectively. No cross-reactivity with anti-VEGF or anti-EGFR was detected. Conclusion: This in-house-developed ELISA is sensitive, accurate, reproducible and suitable for pharmacokinetic studies of ramucirumab.
Details
- Language :
- English
- ISSN :
- 1757-6199
- Volume :
- 13
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Bioanalysis
- Publication Type :
- Academic Journal
- Accession number :
- 33769095
- Full Text :
- https://doi.org/10.4155/bio-2020-0199